Exosomal miR-4516 derived from ovarian cancer stem cells enhanced cisplatin tolerance in ovarian cancer by inhibiting GAS7
- PMID: 38955306
- DOI: 10.1016/j.gene.2024.148738
Exosomal miR-4516 derived from ovarian cancer stem cells enhanced cisplatin tolerance in ovarian cancer by inhibiting GAS7
Abstract
Ovarian cancer (OC) is a devastating disease for women, with chemotherapy resistance taking the lead. Cisplatin has been the first-line therapy for OC for a long time. However, the resistance of OC to cisplatin is an important impediment to its efficacy. Mounting studies showed that ovarian cancer stem cells (OCSCs) affected chemotherapy resistance by secreting exosomes. MicroRNAs (miRNAs) play important roles in exosomes secreted by OCSCs. Here, through the analysis of GEO database (GSE107155) combined with RT-qPCR of OC-related cells/clinical tissues, it was found that hsa-miR-4516 (miR-4516) was significantly up-regulated in OCSCs. Then, OCSCs-derived exosomes were isolated and identified, and it was observed the influence of exosomes on the chemoresistance in SKOV3/cisplatin (SKOV3/DDP) cells. These results manifested that OCSCs-mediated exosomes facilitated the chemoresistance of SKOV3/DDP cells by delivering miR-4516 into them. Growth arrest-specific 7 (GAS7), a downstream target of miR-4516, was determined by bioinformatics prediction combined with molecular biological detection. Next, we up-regulated GAS7 expression and discovered that the promotion of chemoresistance in SKOV3/DDP cells by OCSCs-derived exosomes was significantly impaired. Finally, the mice tumor model of SKOV3/DDP cells was built to estimate the effect of GAS7 over-expression on OC growth. The results showed that GAS7 inhibited the chemoresistance of OC in vivo. In conclusion, our experiments suggested that OCSCs-derived exosomes enhanced OC cisplatin resistance by suppressing GAS7 through the delivery of miR-4516. This study provides a possible target for the treatment of OC DDP resistance.
Keywords: Cisplatin resistance; GAS7; Ovarian cancer; Ovarian cancer stem cells; miR-4516.
Copyright © 2024 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Exosomal miR-21-5p derived from cisplatin-resistant SKOV3 ovarian cancer cells promotes glycolysis and inhibits chemosensitivity of its progenitor SKOV3 cells by targeting PDHA1.Cell Biol Int. 2021 Oct;45(10):2140-2149. doi: 10.1002/cbin.11671. Epub 2021 Jul 29. Cell Biol Int. 2021. PMID: 34288231
-
DDP-resistant ovarian cancer cells-derived exosomal microRNA-30a-5p reduces the resistance of ovarian cancer cells to DDP.Open Biol. 2020 Apr;10(4):190173. doi: 10.1098/rsob.190173. Epub 2020 Apr 29. Open Biol. 2020. Retraction in: Open Biol. 2021 Nov;11(11):210329. doi: 10.1098/rsob.210329. PMID: 32343928 Free PMC article. Retracted.
-
Circ_0078607 increases platinum drug sensitivity via miR-196b-5p/GAS7 axis in ovarian cancer.Epigenetics. 2023 Dec;18(1):2175565. doi: 10.1080/15592294.2023.2175565. Epigenetics. 2023. PMID: 36908025 Free PMC article.
-
A comprehensive survey into the role of microRNAs in ovarian cancer chemoresistance; an updated overview.J Ovarian Res. 2022 Jul 7;15(1):81. doi: 10.1186/s13048-022-01012-1. J Ovarian Res. 2022. PMID: 35799305 Free PMC article. Review.
-
Emerging roles of exosomes in diagnosis, prognosis, and therapeutic potential in ovarian cancer: a comprehensive review.Cancer Gene Ther. 2025 Feb;32(2):149-164. doi: 10.1038/s41417-025-00871-2. Epub 2025 Jan 22. Cancer Gene Ther. 2025. PMID: 39843770 Review.
Cited by
-
Emerging strategies to overcome ovarian cancer: advances in immunotherapy.Front Pharmacol. 2024 Nov 5;15:1490896. doi: 10.3389/fphar.2024.1490896. eCollection 2024. Front Pharmacol. 2024. PMID: 39564107 Free PMC article. Review.
-
Evolving landscape of detection and targeting miRNA/epigenetics for therapeutic strategies in ovarian cancer.Cancer Lett. 2024 Nov 29;611:217357. doi: 10.1016/j.canlet.2024.217357. Online ahead of print. Cancer Lett. 2024. PMID: 39615646 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical